Research will be necessary to determine which type of cyTreg, whether CD4+ pTreg or tTreg, would be more effective killers in the TME, and to determine what engages the cytolytic potential versus other suppressive mechanisms against tumor cells. This evidence concerns the gene CD4 and neoplasm.